Physician profile
John David Moore
NPI 1396731774
$2,664.04
in general payments reported to CMS, 2019-2025
15 companies · $377 in 2025
The $377 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $450 · 2021: $172 · 2022: $286 · 2023: $122 · 2024: $148 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,076.25 | 2019-2020 | |
| Medtronic, INC. | $407.00 | 2021-2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $247.45 | 2019-2025 | Bridion |
| Edwards Lifesciences Corporation | $147.84 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $121.93 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $121.84 | 2020 | |
| Heron Therapeutics, INC. | $118.06 | 2025 | Aponvie, Zynrelef |
| Eagle Pharmaceuticals, INC. | $102.40 | 2023 | |
| Stryker Corporation | $75.48 | 2019 | |
| Chiesi USA, INC. | $71.28 | 2022 | |
| Solventum Corporation | $60.22 | 2025 | |
| Abbott Laboratories | $45.42 | 2020 | |
| Pfizer INC. | $36.59 | 2025 | |
| Cycle Pharmaceuticals INC | $20.04 | 2025 | Venxxiva |
| Medtronic USA, INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.